Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion type Assertion NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_head.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion description "[CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_provenance.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion evidence source_evidence_literature NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_provenance.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion SIO_000772 23730208 NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_provenance.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion wasDerivedFrom befree-2016 NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_provenance.
- NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_assertion wasGeneratedBy ECO_0000203 NP1082941.RAQo0Y42_eBWM7UE4WJTjo-WuwIbKkUoD-4BDjaGZWOg0130_provenance.